Baddi : “Every person in the Pharma industry has to take accountability for Quality production of what they are producing. From the Chairman to the MD, the owner of the company or the board of directors down to the lowest person from whose hands the last product comes” said Mr. Shyam Khante, President of Shyam Khante & Associates.
He was speaking at the exclusive Bio-Pharma Roundtable organised by Lindström India, in association with TiE Chandigarh and BioSpectrum that aimed to explore transformative innovations within the Indian bio-pharma sector including advancements in Bio-Pharma Manufacturing, Sustainability, and Compliance with Global Standards.
“If Medicine is produced with the same intent that what we consume will benefit ourselves, we will see the change” continued Dr. Sanjit Singh Lamba from Trillyum Consulting.
“Until this we understand people, until we engage people, and until unless we motivate people to do work in the right way, things will never happen. You can put all the best shops in place. You can put everything in place, you can do hundreds of trainings, but things will still happen. If they are not motivated, if they are not engaged and they know that it will not affect them it will not happen” Mr. Avtar Singh, RQual Solutions.
The discussion was well be moderated by Dr. Manbeena Chawla, Executive Editor at BioSpectrum India, who persuaded to speakers to delve on immediate industry relevant trends & issues including whether there is a bias against Indian Pharma by US FDA’s or inspections of advanced Regulatory Agencies, or role of AI in Pharma operations, recent techniques to handle Environmental contaminants, outsourcing of sterile components or if the Industry have the right and enough resources to deal with the current scenario issues as well as a core issue like effective utilisation of resources for reaching a state of ” Zero Defects”
Speaking about the roundtable, Manas Kumar, Global Director of Pharma, Strategic Marketing and Business Development APAC, Lindström, We plan to offers a unique opportunity for industry professionals to collaborate, share critical insights, and discuss solutions that will shape the future of the bio-pharma sector. We are committed to driving meaningful conversations that will help elevate industry practices to a global standard.”
This pivotal event delved into the transformative changes shaping the Indian bio-pharma industry, with a spotlight on advancements in manufacturing, sustainability, and workplace hygiene. The Bio-Pharma Roundtable will bring together industry leaders to discuss the evolving landscape of bio-pharma manufacturing, focusing on sustainability, quality assurance, and technological advancements.
As India continues to strengthen its position in the global bio-pharmaceutical arena, the event with a very interactive audience from leading company’s in the Pharma industry, addressed critical issues facing the sector. Topics included USFDA observations, strategies to enhance workwear hygiene standards, and the implementation of quality assurance measures in response to recent global health concerns. The discussions also emphasised the adoption of technological advancements and ensuring compliance with global standards, all while supporting employee well-being.
